129 related articles for article (PubMed ID: 29767381)
1. Novel FGFR2-INA fusion identified in two low-grade mixed neuronal-glial tumors drives oncogenesis via MAPK and PI3K/mTOR pathway activation.
Jain P; Surrey LF; Straka J; Luo M; Lin F; Harding B; Resnick AC; Storm PB; Buccoliero AM; Santi M; Li MM; Waanders AJ
Acta Neuropathol; 2018 Jul; 136(1):167-169. PubMed ID: 29767381
[No Abstract] [Full Text] [Related]
2. FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway.
Huang T; Liu D; Wang Y; Li P; Sun L; Xiong H; Dai Y; Zou M; Yuan X; Qiu H
Cell Physiol Biochem; 2018; 50(4):1332-1345. PubMed ID: 30355943
[TBL] [Abstract][Full Text] [Related]
3. Signaling by FGF Receptor 2, Not FGF Receptor 1, Regulates Myelin Thickness through Activation of ERK1/2-MAPK, Which Promotes mTORC1 Activity in an Akt-Independent Manner.
Furusho M; Ishii A; Bansal R
J Neurosci; 2017 Mar; 37(11):2931-2946. PubMed ID: 28193689
[TBL] [Abstract][Full Text] [Related]
4. Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis.
Yang J; Liao D; Wang Z; Liu F; Wu G
J Surg Res; 2011 Jun; 168(1):97-102. PubMed ID: 20036387
[TBL] [Abstract][Full Text] [Related]
5. FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt signaling and osteoblast survival.
Dufour C; Guenou H; Kaabeche K; Bouvard D; Sanjay A; Marie PJ
Bone; 2008 Jun; 42(6):1032-9. PubMed ID: 18374639
[TBL] [Abstract][Full Text] [Related]
6. It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma.
Jahangiri A; Weiss WA
Clin Cancer Res; 2013 Nov; 19(21):5811-3. PubMed ID: 24097859
[TBL] [Abstract][Full Text] [Related]
7. Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas.
Takahashi Y; Kohashi K; Yamada Y; Endo M; Setsu N; Ishii T; Yamamoto H; Iwamoto Y; Oda Y
Hum Pathol; 2014 May; 45(5):984-93. PubMed ID: 24746202
[TBL] [Abstract][Full Text] [Related]
8. mTOR: a new therapeutic target for pediatric low-grade glioma?
Rodriguez FJ; Raabe EH
CNS Oncol; 2014 Mar; 3(2):89-91. PubMed ID: 25055011
[No Abstract] [Full Text] [Related]
9. Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Liu X; Wang L; Chen J; Ling Q; Wang H; Li S; Li L; Yang S; Xia M; Jing L
Mol Med Rep; 2015 Feb; 11(2):1516-22. PubMed ID: 25351348
[TBL] [Abstract][Full Text] [Related]
10. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
11. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
12. Akt-mTOR signaling is involved in Notch-1-mediated glioma cell survival and proliferation.
Zhao N; Guo Y; Zhang M; Lin L; Zheng Z
Oncol Rep; 2010 May; 23(5):1443-7. PubMed ID: 20372862
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of somatostatin receptors, P44/42 MAPK, and mTOR activation in medulloblastomas and primitive neuroectodermal tumors.
Johnson MD; O'Connell MJ; Silberstein H; Korones D
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):532-8. PubMed ID: 23455179
[TBL] [Abstract][Full Text] [Related]
14. KIF3C is associated with favorable prognosis in glioma patients and may be regulated by PI3K/AKT/mTOR pathway.
Gao Y; Li L; Zheng H; Zhou C; Chen X; Hao B; Cao Y
J Neurooncol; 2020 Feb; 146(3):513-521. PubMed ID: 32020481
[TBL] [Abstract][Full Text] [Related]
15. Schisandrin B suppresses glioma cell metastasis mediated by inhibition of mTOR/MMP-9 signal pathway.
Jiang Y; Zhang Q; Bao J; Du C; Wang J; Tong Q; Liu C
Biomed Pharmacother; 2015 Aug; 74():77-82. PubMed ID: 26349966
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone IIA Affects Autophagy and Apoptosis of Glioma Cells by Inhibiting Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway.
Ding L; Ding L; Wang S; Wang S; Wang W; Wang W; Lv P; Lv P; Zhao D; Zhao D; Chen F; Chen F; Meng T; Meng T; Dong L; Dong L; Qi L; Qi L
Pharmacology; 2017; 99(3-4):188-195. PubMed ID: 27889779
[TBL] [Abstract][Full Text] [Related]
17. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
18. SALL4 suppresses PTEN expression to promote glioma cell proliferation via PI3K/AKT signaling pathway.
Liu C; Wu H; Li Y; Shen L; Yu R; Yin H; Sun T; Sun C; Zhou Y; Du Z
J Neurooncol; 2017 Nov; 135(2):263-272. PubMed ID: 28887597
[TBL] [Abstract][Full Text] [Related]
19. The atypical protein kinase RIOK3 contributes to glioma cell proliferation/survival, migration/invasion and the AKT/mTOR signaling pathway.
Zhang T; Ji D; Wang P; Liang D; Jin L; Shi H; Liu X; Meng Q; Yu R; Gao S
Cancer Lett; 2018 Feb; 415():151-163. PubMed ID: 29233656
[TBL] [Abstract][Full Text] [Related]
20. [Recent studies on PI3K/AKT/mTOR signaling pathway in hematopoietic stem cells].
Zhang YC; Cheng T; Yuan WP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):245-9. PubMed ID: 23484729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
